Leal Health has announced that it presented a poster highlighting disparities in clinical trial participation among diverse ethnic communities at this year's American Association for Cancer Research (AACR) Conference on The Science of Cancer Health Disparities in Racial / Ethnic Minorities and the Medically Underserved.
The poster, titled, "Unveiling disparities in clinical trial participation: Exploring socioeconomic barriers and access to insurance among diverse ethnic groups," was presented by Ritta Jubran, medical director at Leal Health, and highlighted data from a multi-ethnic cohort of 4,525 new patient sign-ups in 2023. The study focused on the impact of several socioeconomic factors, such as insurance coverage and patients' willingness to travel to clinical trial locations, to identify obstacles within underserved communities that contribute to patients' underrepresentation in trials.
Key findings from the study include:
"Our findings from this study reinforce the urgent need to tackle socioeconomic challenges that prevent greater accessibility and inclusivity in clinical trials, especially for historically underrepresented patient communities," said Tzvia Bader, CEO and co-founder, Leal Health in a press release. "Achieving true, real-world representation in clinical trials is a crucial step toward ensuring equity in healthcare. In fact, last year, FDA released guidance for the healthcare industry to enroll more participants from underrepresented racial and ethnic populations into clinical trials. The only way to deliver effective cancer treatments for all patients, regardless of their socioeconomic background or ethnicity, is to remove the barriers that contribute to underrepresentation once and for all."
Leal Health Presents Poster Highlighting Disparities in Clinical Trial Participation Among Diverse Ethnic Groups. (2023, October 10). Cision PR Newswire.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.